Drug Profile
Anti-CD22 monoclonal antibody-toxin conjugate - Galileo Research/the University of Texas
Alternative Names: IMTOX 22 N97A; IMTOX-22; RFB4-N97ALatest Information Update: 13 Feb 2014
Price :
$50
*
At a glance
- Originator Royal Free and University College Medical School; University of Texas Southwestern Medical Center
- Developer Galileo Research; National Cancer Institute (USA)
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported B-cell lymphoma
Most Recent Events
- 13 Feb 2014 No development reported - Phase-I for B-cell lymphoma in USA (Parenteral)
- 24 Nov 2010 Phase-I development is ongoing in USA